Aurora kinase inhibitors as anti-cancer therapy

Anti-Cancer Drugs

Volumn 21, Issue 4, 2010, Pages 339-350

  Lok, Warren ^a   Klein, Rhonda Q ^b   Saif, Muhammad Wasif ^a  

^a YALE CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AT9283; Aurora kinase inhibitors; AZD1152; ENMD 2076; MLN8237; PF03814735; PHA739358; SNS 314; VX680 MK0457; VX689 MK5108

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; 2 [[3 [4 [5 [2 (3 FLUOROANILINO) 2 OXOETHYL] 1H PYRAZOL 3 YLAMINO] 7 QUINAZOLINYLOXY]PROPYL](ETHYL)AMINO]ETHYL DIHYDROGEN PHOSPHATE; 4 [[9 CHLORO 7 (2,6 DIFLUOROPHENYL) 5H PYRIMIDO[5,4 D][2]BENZAZEPIN 2 YL]AMINO]BENZOIC ACID; AMG 900; AURORA A KINASE; AURORA B KINASE; AURORA C KINASE; AURORA KINASE INHIBITOR; BROXURIDINE; CISPLATIN; CYC 116; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DANUSERTIB; DASATINIB; DAUNORUBICIN; DEXAMETHASONE; DOCETAXEL; ENMD 2076; GRANULOCYTE COLONY STIMULATING FACTOR; HESPERADIN; LENALIDOMIDE; MK 5108; MLN 8237; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; PF 03814735; PROTEIN P53; SNS 314; SURVIVIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; ZM 447739;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADENOID CYSTIC CARCINOMA; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ASTROCYTOMA; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CENTROSOME; CHEMOTHERAPY INDUCED EMESIS; CHROMOSOME 17P; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CREATININE BLOOD LEVEL; DIARRHEA; DNA DAMAGE; DRUG DOSE ESCALATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LOCALIZATION; ESOPHAGUS CANCER; FATIGUE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC STABILITY; HEAD AND NECK CANCER; HEART INFARCTION; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CANCER; LARGE CELL LYMPHOMA; LEUKEMIA; LUNG CANCER; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MELANOMA; MESOTHELIOMA; MITOSIS; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NASOPHARYNX CANCER; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHOSPHORYLATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SOMNOLENCE; SQUAMOUS CELL CARCINOMA; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; BENZAMIDES; BENZIMIDAZOLES; CYCLOHEXANECARBOXYLIC ACIDS; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; HUMANS; NEOPLASMS; PHENYLUREA COMPOUNDS; PHOSPHORIC ACID ESTERS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; QUINAZOLINES; THIAZOLES; UREA;

EID: 77949405332     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283350dd1     Document Type: Review

References (123)

1. Adams R, Carmena M, Earnshaw W. Chromosomal passengers and the (aurora) ABCs of mitosis. Trends Cell Biol 2001; 11:49-54.
2. Nigg E. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2001; 2:21-32.
3. Glover D, Leibowitz M, McLean D, Parry H. Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell 1995; 81:95-105.
4. Fu J, Bian M, Jiang Q, Zhang C. Roles of aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 2007; 5:1-10.
5. Ducat D, Zheng Y. Aurora kinases in spindle assembly and chromosome segregation. Exp Cell Res 2004; 301:60-67.
6. Kimura M, Matsuda Y, Yoshioka T, Okano Y. Cell cycle dependent expression and centrosome localization of a third human aurora/ lpl1 related protein kinase, AIK3. J Biol Chem 1999; 274:7334-7340.
7. Giet R, Petretti C, Prigent C. Aurora kinases, aneuploidy and cancer, a coincidence or a real link? Trends Cell Biol 2005; 15:241-250.
8. Andrews P. Aurora kinases: shining lights on the therapeutic horizon? Oncogene 2005; 24:5005-5015.
9. Marumoto T, Zhang D, Saya H. Aurora A-a guardian of poles. Nat Rev Cancer 2005; 5:42-50.
10. Vader G, Lens S. The Aurora kinase family in cell division and cancer. Biochim Biophys Acta 2008; 1786:60-72.
11. Kimura M, Kotani S, Hattori T, Sumi N, Yoshioka T, Todokoro K, et al. Cell cycle dependent expression and spindle pole localization of a novel human protein kinase, Aik, related to Aurora of Drosophila and yeast Ipl1. J Biol Chem 1997; 272:13766-13771.
12. Tanaka M, Ueda A, Kanamori H, Ideguchi H, Yang J, Kitajima S, et al. Cell cycle dependent regulation of human Aurora A transcription is mediated by periodic repression of E4TF1. J Biol Chem 2002; 277:10719-10726.
13. Kimura M, Uchida C, Takano Y, Kitagawa M, Okano Y. Cell cycle dependent regulation of the human Aurora B promoter. Biochem Biophys Res Commun 2004; 316:930-936.
14. Wang I, Chen Y, Hughes D, Petrovic V, Major ML, Park HJ, et al. Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol Cell Biol 2005; 25:10875-10894.
15. Tang C, Chuang C, Hu H, Tang T. The zinc finger domain of Tzfp binds to the tbx motif located at the upstream flanking region of the Aie1 (Aurora C) kinase gene. J Biol Chem 2001; 276:19631-19639.
16. Wittmann T, Wilm M, Karsenti E, Vernos I. TPX2, A novel xenopus MAP involved in spindle pole organization. J Cell Biol 2000; 149:1405-1418.
17. Kufer T, Silljé H, Körner R, Gruss O, Meraldi P, Nigg E. Human TPX2 is required for targeting Aurora-A kinase to the spindle. J Cell Biol 2002; 158:617-623.
18. Bayliss R, Sardon T, Vernos I, Conti E. Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. Mol Cell 2003; 12:851-862.
19. Eyers P, Erikson E, Chen L, Maller J. A novel mechanism for activation of the protein kinase Aurora A. Curr Biol 2003; 13:691-697.
20. Hirota T, Kunitoku N, Sasayama T, Marumoto T, Zhang D, Nitta M, et al. Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 2003; 114:531-532.
21. Hutterer A, Berdnik D, Wirtz-Peitz F, Zigman M, Schleiffer A, Knoblich J. Mitotic activation of the kinase Aurora-A requires its binding partner Bora. Dev Cell 2006; 11:133-134.
22. Pugacheva E, Golemis E. The focal adhesion scaffolding protein HEF1 regulates activation of the Aurora-A and Nek2 kinases at the centrosome. Nat Cell Biol 2005; 7:937-946.
23. Klein U, Nigg E, Gruneberg U. Centromere targeting of the chromosomal passenger complex requires a ternary subcomplex of Borealin, Survivin, and the N-terminal domain of INCENP. Mol Biol Cell 2006; 17:2547-2558.
24. Sessa F, Mapelli M, Ciferri C, Tarricone C, Areces LB, Schneider TR, et al. Mechanism of Aurora B activation by INCENP and inhibition by hesperadin. Mol Cell 2005; 18:379-391.
25. Vader G, Medema R, Lens S. The chromosomal passenger complex: guiding Aurora-B through mitosis. J Cell Biol 2006; 173:833-837.
26. Jelluma N, Brenkman A, Van den Broek N, Cruijsen CW, Van Osch MH, Lens SM, et al. Mps1 phosphorylates Borealin to control Aurora B activity and chromosome alignment. Cell 2008; 132:181-182.
27. Zachos G, Black E, Walker M, Scott MT, Vagnarelli P, Earnshaw WC, et al. Chk1 is required for spindle checkpoint function. Dev Cell 2007; 12:167-168.
28. Han Z, Riefler G, Saam J, Mango S, Schumacher J. The C. elegans tousledlike kinase contributes to chromosome segregation as a substrate and regulator of the Aurora B kinase. Curr Biol 2005; 15:894-904.
29. Li X, Sakashita G, Matsuzaki H, Sugimoto K, Kimura K, Hanaoka F, et al. Direct association with inner centromere protein (INCENP) activates the novel chromosomal passenger protein, Aurora-C. J Biol Chem 2004; 279:47201-47211.
30. Littlepage L, Ruderman J. Identification of a new APC/C recognition domain, the A box, which is required for the Cdh1-dependent destruction of the kinase Aurora-A during mitotic exit. Genes Dev 2002; 16:2274-2285.
31. Stewart S, Fang G. Destruction box-dependent degradation of aurora B is mediated by the anaphase-promoting complex/cyclosome and Cdh1. Cancer Res 2005; 65:8730-8735.
32. Berdnik D, Knoblich J. Drosophila Aurora-A is required for centrosome maturation and actin-dependent asymmetric protein localization during mitosis. Curr Biol 2002; 12:640-647.
33. Hauf S, Cole R, LaTerra S, Zimmer C, Schnapp G, Walter R, et al. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol 2003; 161:281-294.
34. Giet R, Glover D. Drosophila aurora B kinase is required for histone H3 phosphorylation and condensin recruitment during chromosome condensation and to organize the central spindle during cytokinesis. J Cell Biol 2001; 152:669-682.
35. Goto H, Yasui Y, Kawajiri A, Nigg EA, Terada Y, Tatsuka M, et al. Aurora-B regulates the cleavage furrow-specific vimentin phosphorylation in the cytokinetic process. J Biol Chem 2003; 278:8526-8530.
36. Kimmins S, Crosio C, Kotaja N, Hirayama J, Monaco L, Höög C, et al. Differential functions of the Aurora-B and Aurora-C kinases in mammalian spermatogenesis. Mol Endocrinol 2007; 21:726-739.
37. Zhao Z, Lim J, Ng Y, Lim L, Manser E. The GIT-associated kinase PAK targets to the centrosome and regulates Aurora-A. Mol Cell 2005; 20:237-249.
38. De Luca M, Lavia P, Guarguaglini G. A functional interplay between Aurora-A, Plk1 and TPX2 at spindle poles: Plk1 controls centrosomal localization of Aurora-A and TPX2 spindle association. Cell Cycle 2006; 5:296-303.
39. Petretti C, Savoian M, Montembault E, Glover D, Prigent C, Giet R. The PITSLRE/CDK11p58 protein kinase promotes centrosome maturation and bipolar spindle formation. EMBO Rep 2006; 7:418-424.
40. Terada Y, Uetake Y, Kuriyama R. Interaction of Aurora-A and centrosomin at the microtubule-nucleating site in Drosophila and mammalian cells. J Cell Biol 2003; 162:757-763.
41. Mori D, Yano Y, Toyo-oka K, Yoshida N, Yamada M, Muramatsu M, et al. NDEL1 phosphorylation by Aurora-A kinase is essential for centrosomal maturation, separation, and TACC3 recruitment. Mol Cell Biol 2007; 27:352-367.
42. Toji S, Yabuta N, Hosomi T, Nishihara S, Kobayashi T, Suzuki S, et al. The centrosomal protein Lats2 is a phosphorylation target of Aurora-A kinase. Genes Cells 2004; 9:383-397.
43. Barros T, Kinoshita K, Hyman A, Raff J. Aurora A activates D-TACC-Msps complexes exclusively at centrosomes to stabilize centrosomal microtubules. J Cell Biol 2005; 170:1039-1046.
44. Maiato H, Rieder C, Khodjakov A. Kinetochore-driven formation of kinetochore fibers contributes to spindle assembly during animal mitosis. J Cell Biol 2004; 167:831-840.
45. Khodjakov A, Cole R, Oakley B, Rieder C. Centrosome-independent mitotic spindle formation in vertebrates. Curr Biol 2000; 10:59-67.
46. Koffa M, Casanova C, Santarella R, Köcher T, Wilm M, Mattaj I. HURP is part of a Ran-dependent complex involved in spindle formation. Curr Biol 2006; 16:743-754.
47. Seki A, Coppinger J, Jang C, Yates J, Fang G. Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry. Science 2008; 320:1655-1658.
48. Macù rek L, Lindqvist A, Lim D, Lampson MA, Klompmaker R, Freire R, et al. Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature 2008; 455:119-123.
49. Ditchfield C, Johnson V, Tighe A, Ellston R, Haworth C, Johnson T, et al. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 2003; 161:267-280.
50. Murata-Hori M, Wang Y. The kinase activity of aurora B is required for kinetochore-microtubule interactions during mitosis. Curr Biol 2002; 12:894-899.
51. Monier K, Mouradian S, Sullivan K. DNA methylation promotes Aurora-B-driven phosphorylation of histone H3 in chromosomal subdomains. J Cell Sci 2007; 120:101-114.
52. Lan W, Zhang X, Kline-Smith S, Rosasco SE, Barrett-Wilt GA, Shabanowitz J, et al. Aurora B phosphorylates centromeric MCAK and regulates its localization and microtubule depolymerization activity. Curr Biol 2004; 14:273-286.
53. Fang G. Checkpoint protein BubR1 acts synergistically with Mad2 to inhibit anaphase-promoting complex. Mol Biol Cell 2002; 13:755-766.
54. Glotzer M. The molecular requirements for cytokinesis. Science 2005; 307:1735-1739.
55. Yokoyama T, Goto H, Izawa I, Mizutani H, Inagaki M. Aurora-B and Rho-kinase/ROCK, the two cleavage furrow kinases, independently regulate the progression of cytokinesis: possible existence of a novel cleavage furrow kinase phosphorylates ezrin/radixin/moesin (ERM). Genes Cells 2005; 10:127-137.
56. Tang C, Lin C, Tang T. Dynamic localization and functional implications of Aurora-C kinase during male mouse meiosis. Dev Biol 2006; 290:398-410.
57. Sasai K, Katayama H, Stenoien D, Fujii S, Honda R, Kimura M, et al. Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. Cell Motil Cytoskeleton 2004; 59:249-263.
58. Dieterich K, Soto Rifo R, Faure A, Hennebicq S, Ben Amar B, Zahi M, et al. Homozygous mutation of AURKC yields large-headed polyploid spermatozoa and causes male infertility. Nat Genet 2007; 39:661-665.
59. Bischoff J, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 1998; 17:3052-3065.
60. Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998; 20:189-193.
61. Tanner M, Grenman S, Koul A, Johannsson O, Meltzer P, Pejovic T, et al. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res 2000; 6:1833-1839.
62. Watanabe T, Imoto I, Katahira T, Hirasawa A, Ishiwata I, Emi M, et al. Differentially regulated genes as putative targets of amplifications at 20q in ovarian cancers. Jpn J Cancer Res 2002; 93:1114-1122.
63. Rojanala S, Han H, Muñoz R, Browne W, Nagle R, Von Hoff DD, et al. The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer. Mol Cancer Ther 2004; 3:451-457.
64. Tanaka T, Kimura M, Matsunaga K, Fukada D, Mori H, Okano Y. Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer Res 1999; 59:2041-2044.
65. Takahashi T, Futamura M, Yoshimi N, Sano J, Katada M, Takagi Y, et al. Centrosomal kinases, HsAIRK1 and HsAIRK3, are overexpressed in primary colorectal cancers. Jpn J Cancer Res 2000; 91:1007-1014.
66. Gritsko T, Coppola D, Paciga J, Yang L, Sun M, Shelley SA, et al. Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res 2003; 9:1420-1426.
67. Li D, Zhu J, Firozi PF, Abbruzzese JL, Evans DB, Cleary K, et al. Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res 2003; 9:991-997.
68. Jeng Y, Peng S, Lin C, Hsu H. Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 2004; 10:2065-2071.
69. Miyoshi Y, Iwao K, Egawa C, Noguchi S. Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers. Int J Cancer 2001; 92:370-373.
70. Marumoto T, Hirota T, Morisaki T, Kunitoku N, Zhang D, Ichikawa Y, et al. Roles of aurora-A kinase in mitotic entry and G2 checkpoint in mammalian cells. Genes Cells 2002; 7:1173-1182.
71. Anand S, Penrhyn-Lowe S, Venkitaraman A. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 2003; 3:51-62.
72. Meraldi P, Honda R, Nigg E. Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/- cells. EMBO J 2002; 21:483-492.
73. Minn A, Boise L, Thompson C. Expression of Bcl-xL and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage. Genes Dev 1996; 10:2621-2631.
74. Lanni J, Jacks T. Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol Cell Biol 1998; 18:1055-1064.
75. Rieder C, Maiato H. Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell 2004; 7:637-651.
76. Andreassen P, Lohez O, Lacroix F, Margolis R. Tetraploid state induces p53-dependent arrest of nontransformed mammalian cells in G1. Mol Biol Cell 2001; 12:1315-1328.
77. Margolis R, Lohez O, Andreassen P. G1 tetraploidy checkpoint and the suppression of tumorigenesis. J Cell Biochem 2003; 88:673-683.
78. Di Leonardo A, Khan S, Linke S, Greco V, Seidita G, Wahl G. DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. Cancer Res 1997; 57:1013-1019.
79. Khan S, Wahl G. p53 and pRb prevent rereplication in response to microtubule inhibitors by mediating a reversible G1 arrest. Cancer Res 1998; 58:396-401.
80. Casenghi M, Mangiacasale R, Tuynder M, Caillet-Fauquet P, Elhajouji A, Lavia P, et al. p53-independent apoptosis and p53-dependent block of DNA rereplication following mitotic spindle inhibition in human cells. Exp Cell Res 1999; 250:339-350.
81. Vogel C, Kienitz A, Hofmann I, Müller R, Bastians H. Crosstalk of the mitotic spindle assembly checkpoint with p53 to prevent polyploidy. Oncogene 2004; 23:6845-6853.
82. Katayama H, Sasai K, Kawai H, Yuan ZM, Bondaruk J, Suzuki F, et al. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet 2004; 36:55-62.
83. Fujiwara T, Bandi M, Nitta M, Ivanova E, Bronson R, Pellman D. Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature 2005; 437:1043-1047.
84. Liu Q, Kaneko S, Yang L, Feldman RI, Nicosia SV, Chen J, et al. Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem 2004; 279:52175-52182.
85. Ouchi M, Fujiuchi N, Sasai K, Katayama H, Minamishima YA, Ongusaha PP, et al. BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition. J Biol Chem 2004; 279:19643-19648.
86. Yu X, Minter-Dykhouse K, Malureanu L, Zhao WM, Zhang D, Merkle CJ, et al. Chfr is required for tumor suppression and Aurora A regulation. Nat Genet 2005; 37:401-406.
87. Shao S,Wang Y, Jin S, Song Y,Wang X, Fan W, et al. Gadd45a interacts with aurora-A and inhibits its kinase activity. J Biol Chem 2006; 281:28943-28950.
88. Eyers P, Maller J. Regulation of Xenopus Aurora A activation by TPX2. J Biol Chem 2004; 279:9008-9015.
89. Furukawa T, Kanai N, Shiwaku H, Soga N, Uehara A, Horii A. AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer. Oncogene 2006; 25:4831-4839.
90. Yang H, Ou C, Feldman R, Nicosia S, Kruk P, Cheng J. Aurora-A kinase regulates telomerase activity through c-Myc in human ovarian and breast epithelial cells. Cancer Res 2004; 64:463-467.
91. Katayama H, Brinkley W, Sen S. The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metas Rev 2003; 22:451-464.
92. Kanda A, Kawai H, Suto S, Kitajima S, Sato S, Takata T, et al. Aurora-B/ AIM-1 kinase activity is involved in Ras-mediated cell transformation. Oncogene 2005; 24:7266-7272.
93. Ota T, Suto S, Katayama H, Han ZB, Suzuki F, Maeda M, et al. Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res 2002; 62:5168-5177.
94. Araki K, Nozaki K, Ueba T, Tatsuka M, Hashimoto N. High expression of Aurora-B/Aurora and Ipll-like midbody-associated protein (AIM-1) in astrocytomas. J Neurooncol 2004; 67:53-64.
95. Kurai M, Shiozawa T, Shih H, Miyamoto T, Feng YZ, Kashima H, et al. Expression of Aurora kinases A and B in normal, hyperplastic, and malignant human endometrium: Aurora B as a predictor for poor prognosis in endometrial carcinoma. Hum Pathol 2005; 36:1281-1288.
96. Smith S, Bowers N, Betticher D, Gautschi O, Ratschiller D, Hoban PR, et al. Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability. Br J Cancer 2005; 93:719-729.
97. Yang H, Burke T, Dempsey J, Diaz B, Collins E, Toth J, et al. Mitotic requirement for aurora A kinase is bypassed in the absence of aurora B kinase. FEBS Lett 2005; 579:3385-3391.
98. Gizatullin F, Yao Y, Kung V, Harding M, Loda M, Shapiro G. The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res 2006; 66:7668-7677.
99. Young M, Shah N, Chao L, Seeliger M, Milanov ZV, Biggs WH III, et al. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res 2006; 66:1007-1014.
100. Harrington E, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004; 10:262-267.
101. Manfredi M, Ecsedy J, Meetze K, Balani SK, Burenkova O, Chen W, et al. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci U S A 2007; 104:4106-4111.
102. Plummer E, Calvert H, Arkenau H, Lock V, Squires M, Smith DM, et al. A dose-escalation and pharmacodynamic study of AT9283 in patients with refractory solid tumours [abstract 2519]. J Clin Oncol 2008; 20 (Suppl):3158-3168.
103. Foran J, Ravandi F, O'Brien S, Borthakur G, Rios M, Boone P, et al. Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor, in patients with refractory leukemia [abstract 2518]. J Clin Oncol 2008; 20 (Suppl):7987-7990.
104. Wilkinson R, Odedra R, Heaton S, Wedge SR, Keen NJ, Crafter C, et al. AZD1152, a selective inhibitor of aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 2007; 13:3682-3688.
105. Yang J, Ikezoe T, Nishioka C, Tasaka T, Taniguchi A, Kuwayama Y, et al. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood 2007; 110:2034-2040.
106. Evans RP, Naber C, Steffler T, Checkland T, Maxwell CA, Keats JJ, et al. The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Br J Haematol 2008; 140:295-302.
107. Schellens J, Boss D,Witteveen P, Zandvliet A, Beijnen JH, Voogel-Fuchs M, et al. Phase I and pharmacological study of the novel aurora kinase inhibitor AZD1152 [abstract 3008]. J Clin Oncol 2006; 20 (Suppl):295-302.
108. Houghton P, Morton C, Maris J, Courtright J, Carol H, Lock RB, et al. Pediatric preclinical testing program (PPTP) evaluation of the Aurora A Kinase Inhibitor MLN8237. Pediatric Preclinical Testing Program Meeting 2008; abstract 2997.
109. Smith M, Houghton P, Morton C, Maris JM, Courtright J, Carol H, et al. Pediatric preclinical testing program (PPTP) stage 2 testing of the Aurora A kinase inhibitor MLN8237. Pediatric Preclinical Testing Program Meeting 2008; abstract 286.
110. Gorgun G, Calabrese E, Mani M, Hideshima T, Ikeda H, Perrone G, et al. A novel Aurora-a kinase inhibitor MLN8237 induces cytotoxicity and cell cycle arrest in experimental multiple myeloma models. ASH Meeting 2008; abstract 1719.
111. Huck J, Zhang M, Hyer M, Manfredi M. Anti-tumor activity of the Aurora a inhibitor MLN8237 in diffuse large B-cell lymphoma preclinical models. ASH Meeting 2008; abstract 1592.
112. Infante J, Dees E, Cohen R, Burris H, O'Neil B, Murphy P, et al. Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MLN8237, a selective Aurora A kinase inhibitor, in the United States. EORTC-NCI-AACR 20th International Symposium 2008; abstract 280.
113. Jones S, Burris HA, Dumez H, Infante JR, Fowst C, Gerletti P, et al. Phase I accelerated dose-escalation, pharmacokinetic (PK) and pharmacodynamic study of PF-03814735, an oral aurora kinase inhibitor, in patients with advanced solid tumors: preliminary results [abstract 2517]. J Clin Oncol 2008; 20 (Suppl).
114. Carpinelli P, Ceruti R, Giorgini ML, Cappella P, Gianellini L, Croci V, et al. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 2007; 6 (12 Pt 1):3158-3168.
115. Modugno M, Casale E, Soncini C, Rosettani P, Colombo R, Lupi R, et al. Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. Cancer Res 2007; 67:7987-7990.
116. Cohen R, Jones S, Von Mehren M, Cheng J, Spiegel DM, Laffranchi B, et al. Phase I study of the pan aurora kinases (AKs) inhibitor PHA-739358 administered as a 24 h infusion without/with G-CSF in a 14-day cycle in patients with advanced solid tumors [abstract 2520]. J Clin Oncol 2008; 20 (Suppl).
117. Robert F, Hurwitz H, Verschraegen C, Advani R, Berman C, Taverna P, et al. Phase 1 trial of SNS-314, a novel selective inhibitor of aurora kinases A, B, and C, in advanced solid tumor patients [abstract 14642]. J Clin Oncol 2008; 20 (Suppl).
118. Carpinelli P, Moll J. Aurora kinases and their inhibitors: more than one target and one drug. Adv Exp Med Biol 2008; 610:54-73.
119. Giles F, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman S. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007; 109:500-502.
120. Nair J, De Stanchina E, Schwartz G. The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo. Clin Cancer Res 2009; 15:2022-2030.
121. Tao Y, Zhang P, Girdler F, Frascogna V, Castedo M, Bourhis J, et al. Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152. Oncogene 2008; 27:3244-3255.
122. Sun C, Chan F, Briassouli P, Linardopoulos S. Aurora kinase inhibition downregulates NF-kappaB and sensitises tumour cells to chemotherapeutic agents. Biochem Biophys Res Commun 2007; 352:220-225.
123. Lee E, Frolov A, Li R, Ayala G, Greenberg N. Targeting Aurora kinases for the treatment of prostate cancer. Cancer Res 2006; 66:4996-5002.